In our study, we found that injecting parenteral ω-3 PUFA solutions reduced IL-1β, TNF-α, IL-6, IL-10, IFN-γ, and IL-17 levels and hindered the secretion of multi-organ injury markers induced by CLP treatment, indicating the protective role of ω-3 PUFAs in sepsis. This evidence concerns the gene IL17A and Sepsis.